Gosset Apitope General Information
Apitope developed a proprietary peptide-based immunotherapy platform (“apitopes®”) targeting the underlying immune dysregulation in autoimmune diseases. Lead program ATX-MS1467 showed positive safety and early efficacy signals in Phase I trials for multiple sclerosis and advanced to a Merck Serono-partnered Phase IIa trial. Other pipeline candidates target conditions such as Graves’ disease, hemophilia A with FVIII inhibitors, uveitis, myocarditis, and rheumatoid arthritis. The company’s approach aims to restore immune tolerance without global immunosuppression. In August 2021 it was acquired by Worg Pharmaceuticals; current development status may be under Worg’s management but legacy data shows several active programs at various stages from discovery through early clinical trials.
Contact Information
Belgium
Drug Pipeline
Key Partnerships
Merck Serono (notably on MS program), European Commission funding on some projects, Abzena collaboration on manufacturing support for certain assets like ATX-F8–117
Apitope Funding
No funding data available